Investigations currently going on in the New York State Attorney General's office are looking into charges that analysts at investment banks often give misleading advice on companies in order to support the banks' M&A activities. Such conflicts of interest aren't hard to understand. But for medical device companies, the implicit notion--that investment banks are friendly places that bend over backward to say nice things--runs counter to their experience.
You may also be interested in...
Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.
The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular.
As part of efforts to “renovate” its good clinical practice (GCP) framework, the International Council for Harmonisation has framed new overarching GCP principles that can be applied to diverse trial types and data sources.